EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study

Gianluca Avallone iD, Carlo Alberto Maronese iD, Martina Zussino, Simona Muratori, Silvia Mariel Ferrucci, Pietro Quaglino, Elisabetta Manni, Marco Romanelli, Clara De Simone, Caterina Foti, Luigi Gargiulo, Vincenzo Maione iD und 22 weitere

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17742 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Gianluca Avallone und 33 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Omalizumab, Pemphigoid, Bullous, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease worldwide. In the difficult‐to‐treat BP or if standard therapies are contraindicated, the use of biologics may be also considered although there is no strong evidence supporting their use. This study aimed to investigate clinical and diagnostic findings as well as treatment outcomes among patients diagnosed with BP and undergoing omalizumab or dupilumab in a real‐world setting. A multicenter retrospective cohort study was performed across 15 Italian tertiary referral hospital. Medical records of 2435 BP patients were screened, identifying 58 (2.3%) Caucasian patients who met the inclusion criteria. Within this study population, 39 (67.2%) were treated with dupilumab and 19 (32.8%) received omalizumab. Disease control was achieved in 90.6% of dupilumab‐treated patients and complete remission on minimal therapy was observed in 71.0%. Omalizumab‐treated patients achieved disease control in 77.8% of cases and 64.7% obtained complete remission on minimal therapy. Log‐rank test comparing relapse rate between treatment groups was not significant ( p = 0.58). Finally, parameter estimates associated with the fixed effect of time were consistently negative, indicating a generally significant ( p = < 0.05) decrease in scores over time for patients treated with both biologics. This cohort of patients undergoing dupilumab or omalizumab adds to the existing evidence concerning the effectiveness of biologic agents in BP. Both biologics seem to be promising treatment adjuvants in the management of BP, with dupilumab showing a descriptive trend toward better outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabPemphigoid, BullousAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesMaleFemaleAgedTreatment OutcomeMiddle AgedAged, 80 and overRemission InductionItalyAdultRecurrence

Stichwörter der Autor:innen

autoimmune bullous diseasesbullous pemphigoiddupilumabgliptin‐associated bullous pemphigoidimmunotherapy‐associated bullous pemphigoidomalizumab

Substanzen

OmalizumabdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Section of Dermatology, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Dermatology Unit, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, ERN-SKIN Member, Rome, Italy.

ORCID-Profile: Gianluca Avallone, Carlo Alberto Maronese, Vincenzo Maione, Anna Campanati, Emanuele Cozzani, Simone Ribero

Zitieren

APA

Avallone, G., Maronese, C. A., Zussino, M., Muratori, S., Ferrucci, S. M., Quaglino, P., Manni, E., Romanelli, M., De Simone, C., Foti, C., Gargiulo, L., Maione, V., Calzavara-Pinton, P., Bardazzi, F., Piraccini, B. M., Antiga, E., Rech, G., Balestri, R., Vezzoli, P., …, & DUO—DUpilumab and Omalizumab in Bullous Pemphigoid Study Group (2025). Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17742

Vancouver

Avallone G, Maronese CA, Zussino M, Muratori S, Ferrucci SM, Quaglino P, et al. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17742

BibTeX
@article{Avallone2025,
  author = {Avallone, Gianluca and Maronese, Carlo Alberto and Zussino, Martina and Muratori, Simona and Ferrucci, Silvia Mariel and Quaglino, Pietro and Manni, Elisabetta and Romanelli, Marco and De Simone, Clara and Foti, Caterina and Gargiulo, Luigi and Maione, Vincenzo and Calzavara-Pinton, Piergiacomo and Bardazzi, Federico and Piraccini, Bianca Maria and Antiga, Emiliano and Rech, Giulia and Balestri, Riccardo and Vezzoli, Pamela and Sena, Paolo and Esposito, Maria and Fargnoli, Maria Concetta and Termini, Davide and Valtellini, Luca and Satta, Rosanna Rita and Vassallo, Camilla and Provini, Alessia and Di Zenzo, Giovanni and Campanati, Anna and Caproni, Marzia and Cozzani, Emanuele and Ribero, Simone and Marzano, Angelo Valerio and DUO—DUpilumab and Omalizumab in Bullous Pemphigoid Study Group, DUO—DUpilumab and Omalizumab in Bullous Pemphigoid Study Group},
  title = {Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17742}
}
Kostenlos starten →